2,500
Participants
Start Date
June 1, 2019
Primary Completion Date
December 1, 2026
Study Completion Date
December 31, 2026
Using tissue and peripheral blood proteomics to distinguish the benign and malignant nature of lung cancer in patients, as well as to evaluate therapeutic efficacy and long-term prognosis during the t
Peripheral blood samples from enrolled participants will be drawn, or lesion tissues will be obtained through procedures such as biopsy or surgery, followed by quantitative proteomics analysis using mass spectrometry.
RECRUITING
the First Affiliated of Guangzhou Medical University, Guangzhou
The First Affiliated Hospital of Guangzhou Medical University
OTHER